Pharm Exec recently asked
the Tufts Center for the Study of Drug Development (TCSDD) to summarize new
survey research—partly commissioned by a grant from Amgen—that documents the
scope of the threat and identifies the structural roots of the shortages. In a
larger sense, the study underscores how effective management of the drug supply
chain is emerging as something much more than an engineering feat: instead it’s
a societal obligation.
TCSDD developed a
two-part methodology that entailed building a database of current drug shortages
and conducting interviews with experience hospital pharmacists to gather
first-hand knowledge of how drug shortages are managed and the challenges that
they pose. Tufts CSDD staff gathered publicly available data on 240 drug
shortages occurring between 2001 and February 2012, from lists maintained by the
ASHP and the FDA.Continue reading here
No comments:
Post a Comment